Towards an individualised target concentration of adalimumab in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 7, 2014, Pages 1428-1429

  Ducourau, Emilie ^a,b   Ternant, David ^a,b   Lequerré, Thierry ^c,d   Fuzibet, Piéra ^a,b   Le Loët, Xavier ^c,d   Watier, Hervé ^a,b   Goupille, Philippe ^a,b   Paintaud, Gilles ^a,b   Vittecoq, Olivier ^c,d   Mulleman, Denis ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB;

CONCENTRATION RESPONSE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT INDICATION;

ANTI-TNF; PHARMACOKINETICS; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TREATMENT OUTCOME;

EID: 84902274701     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204971     Document Type: Letter

References (6)

1. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6. (Pubitemid 46999794)
2. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. Key findings towards optimising adalimumab treatment: The concentration-effect curve. Ann Rheum Dis 2014. Published Online First: 10 Dec 2013. doi:10.1136/annrheumdis-2013-204172.
3. Mulleman D, Ducourau E, Paintaud G, et al. Should anti-TNF-alpha drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine 2012;79:109-12.
4. Blache C, Lequerre T, Roucheux A, et al. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept. Rheumatology (Oxford) 2011;50:1814-22.
5. Kirby S, Brain P, Jones B. Fitting E(max) models to clinical trial dose-response data. Pharm Stat 2011;10:143-9.
6. Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35. (Pubitemid 47585417)